These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 20127959

  • 1. Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F(ab')2 antibody.
    Aarts F, Boerman OC, Sharkey RM, Hendriks T, Chang CH, McBride WJ, Bleichrodt RP, Oyen WJ, Goldenberg DM.
    Cancer; 2010 Feb 15; 116(4 Suppl):1111-7. PubMed ID: 20127959
    [Abstract] [Full Text] [Related]

  • 2. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
    Barbet J, Peltier P, Bardet S, Vuillez JP, Bachelot I, Denet S, Olivier P, Leccia F, Corcuff B, Huglo D, Proye C, Rouvier E, Meyer P, Chatal JF.
    J Nucl Med; 1998 Jul 15; 39(7):1172-8. PubMed ID: 9669389
    [Abstract] [Full Text] [Related]

  • 3. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
    van Schaijk FG, Oosterwijk E, Soede AC, Broekema M, Frielink C, McBride WJ, Goldenberg DM, Corstens FH, Boerman OC.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
    [Abstract] [Full Text] [Related]

  • 4. Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.
    Bodet-Milin C, Faivre-Chauvet A, Carlier T, Rauscher A, Bourgeois M, Cerato E, Rohmer V, Couturier O, Drui D, Goldenberg DM, Sharkey RM, Barbet J, Kraeber-Bodere F.
    J Nucl Med; 2016 Oct 01; 57(10):1505-1511. PubMed ID: 27230928
    [Abstract] [Full Text] [Related]

  • 5. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
    Karacay H, Sharkey RM, McBride WJ, Griffiths GL, Qu Z, Chang K, Hansen HJ, Goldenberg DM.
    Bioconjug Chem; 2002 Oct 01; 13(5):1054-70. PubMed ID: 12236788
    [Abstract] [Full Text] [Related]

  • 6. Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer.
    Vuillez JP, Moro D, Brichon PY, Rouvier E, Brambilla E, Barbet J, Peltier P, Meyer P, Sarrazin R, Brambilla C.
    J Nucl Med; 1997 Apr 01; 38(4):507-11. PubMed ID: 9098191
    [Abstract] [Full Text] [Related]

  • 7. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.
    McBride WJ, Zanzonico P, Sharkey RM, Norén C, Karacay H, Rossi EA, Losman MJ, Brard PY, Chang CH, Larson SM, Goldenberg DM.
    J Nucl Med; 2006 Oct 01; 47(10):1678-88. PubMed ID: 17015905
    [Abstract] [Full Text] [Related]

  • 8. Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesin-antibody complexes and targeting with high specific radioactivity labeled polymer-drug conjugates.
    Patil V, Gada K, Panwar R, Varvarigou A, Majewski S, Weisenberger A, Ferris C, Tekabe Y, Khaw BA.
    Eur J Nucl Med Mol Imaging; 2012 May 01; 39(5):824-39. PubMed ID: 22302089
    [Abstract] [Full Text] [Related]

  • 9. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
    Cardillo TM, Karacay H, Goldenberg DM, Yeldell D, Chang CH, Modrak DE, Sharkey RM, Gold DV.
    Clin Cancer Res; 2004 May 15; 10(10):3552-61. PubMed ID: 15161715
    [Abstract] [Full Text] [Related]

  • 10. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
    Kraeber-Bodéré F, Faibre-Chauvet A, Saï-Maurel C, Gautherot E, Fiche M, Campion L, Le Boterff J, Barbet J, Chatal JF, Thédrez P.
    J Nucl Med; 1999 Jan 15; 40(1):198-204. PubMed ID: 9935077
    [Abstract] [Full Text] [Related]

  • 11. Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response.
    Le Doussal JM, Chetanneau A, Gruaz-Guyon A, Martin M, Gautherot E, Lehur PA, Chatal JF, Delaage M, Barbet J.
    J Nucl Med; 1993 Oct 15; 34(10):1662-71. PubMed ID: 8410279
    [Abstract] [Full Text] [Related]

  • 12. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY, Chu DZ, Yamauchi D, Odom-Maryon TL, Williams LE, Liu A, Esteban JM, Wu AM, Primus FJ, Beatty JD, Shively JE, Raubitschek AA.
    J Nucl Med; 1998 Dec 15; 39(12):2097-104. PubMed ID: 9867150
    [Abstract] [Full Text] [Related]

  • 13. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
    Storto G, Buchegger F, Waibel R, Kuenzi G, Offord RE, Schubiger PA, Gillet M, Delaloye AB.
    Cancer Biother Radiopharm; 2001 Oct 15; 16(5):371-9. PubMed ID: 11776754
    [Abstract] [Full Text] [Related]

  • 14. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
    Gautherot E, Rouvier E, Daniel L, Loucif E, Bouhou J, Manetti C, Martin M, Le Doussal JM, Barbet J.
    J Nucl Med; 2000 Mar 15; 41(3):480-7. PubMed ID: 10716323
    [Abstract] [Full Text] [Related]

  • 15. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial.
    Vuillez JP, Kraeber-Bodéré F, Moro D, Bardiès M, Douillard JY, Gautherot E, Rouvier E, Barbet J, Garban F, Moreau P, Chatal JF.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3259s-3267s. PubMed ID: 10541373
    [Abstract] [Full Text] [Related]

  • 16. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
    Gautherot E, Le Doussal JM, Bouhou J, Manetti C, Martin M, Rouvier E, Barbet J.
    J Nucl Med; 1998 Nov 15; 39(11):1937-43. PubMed ID: 9829586
    [Abstract] [Full Text] [Related]

  • 17. Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide.
    Karacay H, McBride WJ, Griffiths GL, Sharkey RM, Barbet J, Hansen HJ, Goldenberg DM.
    Bioconjug Chem; 2000 Nov 15; 11(6):842-54. PubMed ID: 11087333
    [Abstract] [Full Text] [Related]

  • 18. Metastatic colorectal cancer: radioimmunoscintigraphy with a stabilized In-111-labeled F(ab')2 fragment of an anti-CEA monoclonal antibody.
    Lamki LM, Patt YZ, Rosenblum MG, Shanken LJ, Thompson LB, Schweighardt SA, Frincke JM, Murray JL.
    Radiology; 1990 Jan 15; 174(1):147-51. PubMed ID: 2294542
    [Abstract] [Full Text] [Related]

  • 19. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
    Hosono M, Hosono MN, Kraeber-Bodéré F, Devys A, Thédrez P, Fiche M, Gautherot E, Barbet J, Chatal JF.
    J Nucl Med; 1998 Sep 15; 39(9):1608-13. PubMed ID: 9744353
    [Abstract] [Full Text] [Related]

  • 20. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
    Behr TM, Sharkey RM, Juweid MI, Dunn RM, Ying Z, Zhang CH, Siegel JA, Gold DV, Goldenberg DM.
    Cancer Res; 1996 Apr 15; 56(8):1805-16. PubMed ID: 8620497
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.